ESPR · As filed with the SEC
Esperion Therapeutics income statement, by quarter
The statement as Esperion Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Statements of Operations and Comprehensive Loss · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025† 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 |
|---|---|---|---|---|---|
| Revenues: | |||||
| Total Revenues | 80,104 | 168,446† | 87,309 | 82,385 | 64,995 |
| Product sales, net | 43,391 | 43,723† | 40,659 | 40,274 | 34,913 |
| Collaboration revenue | 36,713 | 124,723† | 46,650 | 42,111 | 30,082 |
| Operating expenses: | |||||
| Cost of goods sold | 34,573 | — | 41,289 | 28,543 | 31,538 |
| Research and development | 8,988 | 13,926† | 14,131 | 7,238 | 12,557 |
| Selling, general and administrative | 43,124 | 41,433† | 41,848 | 39,509 | 42,996 |
| Total operating expenses | 86,685 | 83,213† | 97,268 | 75,290 | 87,091 |
| Loss from operations | (6,581) | 85,233† | (9,959) | 7,095 | (22,096) |
| Interest expense | (19,798) | (22,636)† | (22,051) | (20,486) | (19,431) |
| Loss on extinguishment of debt and exchange transaction | — | 0† | 0 | 0 | — |
| Other income, net | 1,183 | 1,075† | 677 | 666 | 1,072 |
| Net loss | (25,196) | 61,831† | (31,333) | (12,725) | (40,455) |
| Net loss per common share - basic (in dollars per share) | (0.10) | — | (0.16) | (0.06) | (0.21) |
| Net loss per common share - diluted (in dollars per share) | (0.10) | — | (0.16) | (0.06) | (0.21) |
| Weighted-average shares outstanding - basic (in shares) | 251,353,086 | — | 200,736,136 | 197,546,239 | 196,127,948 |
| Weighted-average shares outstanding - diluted (in shares) | 251,353,086 | — | 200,736,136 | 197,546,239 | 196,127,948 |
| Comprehensive loss | (25,196) | 61,831† | (31,333) | (12,725) | (40,455) |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.